Alebund Pharmaceutical Raises RMB 550 Million in Series C Financing Round

Alebund Pharmaceuticals, an integrated biopharmaceutical company specializing in innovative therapies for renal diseases, has successfully closed a Series C financing round totaling RMB 550 million. The funding was led by a renowned healthcare fund, with participation from Yangzhou Guojin Investment Group Co. Ltd. and Kingray Capital.

The capital raised will be strategically allocated to accelerate the development and commercialization of Alebund’s renal disease pipeline. Key initiatives include advancing the new drug application (NDA) process in China for AP301, a best-in-class iron-based phosphate binder, and conducting its global pivotal study. Additionally, the funding will support Phase II clinical trials in both the U.S. and China for AP306, a first-in-class pan phosphate transporter inhibitor, and facilitate the commercial expansion of Mircera® in China.

Chronic kidney disease (CKD) poses a growing global public health challenge, with increasing incidence rates annually. Alebund is dedicated to developing treatments for various renal conditions, including CKD and its complications, IgA nephropathy, diabetic kidney disease, focal segmental glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD). The company has established a small molecule production facility in Yangzhou, now operational, and has formed a dedicated commercial team in China to promote Mircera® and prepare for the launch of future pipeline products.

Dr. Gavin Xia, Co-founder, Chairman, and CEO of Alebund, expressed that the successful Series C financing underscores the critical importance of developing new therapies for chronic kidney diseases and reflects market confidence in Alebund’s team. He stated, “We will accelerate the development of Alebund’s innovative pipeline globally and expand our commercial footprint in China, to strengthen our influence in renal diseases area, to bring better therapeutic options to patients in China and globally as soon as possible.”

Founded in Shanghai in early 2018, Alebund Pharmaceuticals focuses on the discovery, development, production, and commercialization of novel therapies for kidney diseases and related chronic conditions. The company has developed a diversified pipeline targeting various renal indications and has established manufacturing and commercial operations to support its mission.

The completion of this financing round positions Alebund Pharmaceuticals to enhance its research and development efforts, expand its market presence, and continue its commitment to providing innovative therapeutic options for patients with renal diseases.